[Antibody screening of commercially available immunoglobulins. Erythrocyte-, HLA- and autoantibodies (author's transl)].
A great number of commercially available immunoglobulins was screened for erythrocyte-, HLA- and autoantibodies. Isoagglutinin titers were in general low, hemolysins were not detected. No preparation was found to contain detectable amounts of autoantibodies versus nuclei, mitochondria, smooth muscle or parietal cells. Yet 7 out of 22 immunoglobulin charges contained irregular red cell antibodies, aside of polyspecific albumin reactive types in 5 cases a distinct anti-D. Only the preparation examined in 1975 contained polyspecific HLA-antibodies. 1977/78 all preparations for intravenous use were free from undesired antibodies, while those for intramuscular application were contaminated with irregular red cell antibodies 1975 as well as 1978. Because of their low strength these antibodies imply no clinical risk. Nonetheless an improvement of the official rules for the production and control of immunoglobulin preparations is inevitable to avoid damage caused by exceptional charges with extremely strong antibodies of this type.
D000906:Antibodies / Q000032:analysis*; D001323:Autoantibodies / Q000032:analysis*; D004912:Erythrocytes / Q000276:immunology*; D006680:HLA Antigens; D006460:Hemolysin Proteins / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins; D007518:Isoantibodies / Q000032:analysis
D000906:Antibodies; D001323:Autoantibodies; D006680:HLA Antigens; D006460:Hemolysin Proteins; D007136:Immunoglobulins; D007518:Isoantibodies
Antikörperscreening an kommerziellen Immunglobulinpräparaten. Erythrozyten-, HLA- und Autoantikörper.